| An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans CB Kurtz, YA Millet, MK Puurunen, M Perreault, MR Charbonneau, ... Science translational medicine 11 (475), eaau7975, 2019 | 305 | 2019 |
| SBML Level 3: an extensible format for the exchange and reuse of biological models SM Keating, D Waltemath, M König, F Zhang, A Dräger, C Chaouiya, ... Molecular systems biology 16 (8), e9110, 2020 | 211 | 2020 |
| Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood MS Chatterjee, WS Denney, H Jing, SL Diamond PLoS computational biology 6 (9), e1000950, 2010 | 195 | 2010 |
| Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow UM Okorie, WS Denney, MS Chatterjee, KB Neeves, SL Diamond Blood, The Journal of the American Society of Hematology 111 (7), 3507-3513, 2008 | 152 | 2008 |
| Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study MK Puurunen, J Vockley, SL Searle, SJ Sacharow, JA Phillips III, ... Nature metabolism 3 (8), 1125-1132, 2021 | 108 | 2021 |
| AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients A Kaufman, L Abuqayyas, WS Denney, EJ Tillman, T Rolph Cell Reports Medicine 1 (4), 2020 | 103 | 2020 |
| Simple, automatic noncompartmental analysis: the PKNCA R package C Buckeridge, S Duvvuri, WS Denney J Pharmacokinet Pharmacodyn 42 (1), 11-107, 2015 | 101 | 2015 |
| Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974) SR Sinclair, SA Kane, BJ Van der Schueren, A Xiao, KJ Willson, J Boyle, ... British journal of clinical pharmacology 69 (1), 15-22, 2010 | 95 | 2010 |
| Stochastic modeling of blood coagulation initiation K Lo, WS Denney, SL Diamond Pathophysiology of haemostasis and thrombosis 34 (2-3), 80-90, 2006 | 87 | 2006 |
| Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes NB Amin, N Aggarwal, D Pall, G Paragh, WS Denney, V Le, M Riggs, ... Diabetes, Obesity and Metabolism 17 (8), 751-759, 2015 | 52 | 2015 |
| Pharmacokinetics and pharmacodynamics of PF‐05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects WS Denney, GE Sonnenberg, S Carvajal‐Gonzalez, T Tuthill, ... British journal of clinical pharmacology 83 (2), 326-338, 2017 | 49 | 2017 |
| Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients ML Reitman, V Dishy, A Moreau, WS Denney, C Liu, WK Kraft, AV Mejia, ... The Journal of Clinical Pharmacology 52 (9), 1306-1316, 2012 | 42 | 2012 |
| Neutrophil-bead collision assay: pharmacologically induced changes in membrane mechanics regulate the PSGL-1/P-selectin adhesion lifetime KE Edmondson, WS Denney, SL Diamond Biophysical journal 89 (5), 3603-3614, 2005 | 38 | 2005 |
| An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM DJ Conrado, WS Denney, D Chen, K Ito Journal of pharmacokinetics and pharmacodynamics 41, 581-598, 2014 | 37 | 2014 |
| Functional phenotyping of human plasma using a 361‐fluorogenic substrate biosensing microarray DN Gosalia, WS Denney, CM Salisbury, JA Ellman, SL Diamond Biotechnology and bioengineering 94 (6), 1099-1110, 2006 | 37 | 2006 |
| Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: implications for trial design and clinical practice JS Bajaj, PP Bloom, RT Chung, TI Hassanein, M Padilla-Martinez, ... Official journal of the American College of Gastroenterology| ACG 115 (5 …, 2020 | 36 | 2020 |
| Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates C Kurtz, WS Denney, L Blankstein, SE Guilmain, S Machinani, J Kotula, ... Clinical and translational science 11 (2), 200-207, 2018 | 32 | 2018 |
| Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent SD Edmondson, MS SinhaRroy, H Nagabukuro, WS Denney, TF Frenki US Patent App. 13/500,574, 2012 | 26 | 2012 |
| Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator R Sharma, J Litchfield, K Atkinson, H Eng, NB Amin, WS Denney, ... Drug Metabolism and Disposition 42 (11), 1926-1939, 2014 | 23 | 2014 |
| Prediction of phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling CR Gibson, A Bergman, P Lu, F Kesisoglou, WS Denney, E Mulrooney Xenobiotica 39 (9), 637-648, 2009 | 23 | 2009 |
Scott L. DiamondUniversity of Pennsylvania在 seas.upenn.edu 的电子邮件经过验证
